Hollie Franklin, Author at Drugs in Context

Real-world management of abnormal scarring using topical silicone gel: expert consensus and case series from the Asian SCARS Expert Group

Xiaonan Yang, Visnu Lohsiriwat, Frank Chun Shin Chang, Tan Thiam Chye, Catherine J Howard, Liang Qiao, Steven W Shaw, Tu Nguyen Anh Tran, Chan Yung, Daniel Dellosa, Dinesh Nagrale

Article Type

Case Series

Published

03 Jul 2023

This article presents a case series including patients with hypertrophic and keloid scars treated with Dermatix, showing that Dermatix is effective for scar treatment and prevention, as well as expert consensus supporting the safe and effective use of Dermatix.

Tinea pedis: an updated review

Alexander KC Leung, Benjamin Barankin, Joseph M Lam, Kin Fon Leong, Kam Lun Hon

Article Type

Review

Published

29 Jun 2023

This review aims to familiarize physicians with the clinical features, diagnosis and management of tinea pedis.

Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann

Article Type

Review

Published

27 Jun 2023

This article aimed to assess the prevalence of individuals with one or more risk factors for severe COVID-19 along with contraindications and potential drug–drug interactions due to ritonavir-containing COVID-19 therapy.

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors

Darren MC Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, Hong Kong Society of Uro-Oncology

Article Type

Original Research

Published

21 Jun 2023

In this study, the authors investigated the toxicity and efficacy of cabozantinib in Chinese patients who progressed on VEGFR TKIs and/or ICIs in real-life clinical practice.

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy

Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti

Article Type

Original Research

Published

20 Jun 2023

This real-life study investigated the link between clinical complexity and quality of life of patients with HR+/HER2– advanced breast cancer treated with CDK4/6 inhibitors.